Kilinux

Main Menu

  • Home
  • Development agency
  • Major application
  • Sweden project
  • Swedish economy
  • Swedish international

Kilinux

Header Banner

Kilinux

  • Home
  • Development agency
  • Major application
  • Sweden project
  • Swedish economy
  • Swedish international
Sweden project
Home›Sweden project›Swedish company Sobi licenses loncastuximab tesirine to ADC Therapeutics for upfront payment of $55 million

Swedish company Sobi licenses loncastuximab tesirine to ADC Therapeutics for upfront payment of $55 million

By Suk Bouffard
July 8, 2022
0
0

(RTTNews) – Swedish Orphan Biovitrum AB or Sobi (SWTUY.PK), a specialty biopharmaceutical company, announced on Friday an exclusive license agreement with ADC Therapeutics SA for loncastuximab tesirine.

Under the terms of the agreement, Sobi has been granted the rights to develop and commercialize loncastuximab tesirine for all hematology and solid tumor indications in Europe and most international markets outside of the United States, Greater China, Singapore and Japan.

Sobi will pay $55 million in upfront payment, which will be funded from Sobi’s cash reserves, and $50 million upon EU regulatory approval in the 3rd line DLBCL.

The company will also pay royalties between the mid-teens and mid-twenties percent of net sales and up to approximately $330 million in potential regulatory and commercial milestones.

As loncastuximab tesirine is under development for other indications, Sobi will contribute 25% of direct development costs up to a cap of $10 million per year. ADC Therapeutics is responsible for clinical development and product delivery to Sobi.

Loncastuximab tesirine is an antibody-drug conjugate or ADC directed against CD19, a protein expressed on the surface of B cells.

In April 2021, the U.S. Food and Drug Administration granted accelerated approval for ZYNLONTA, the U.S. brand name of loncastuximab tesirine, as a single-agent treatment for adult patients with relapsed or refractory DLBCL after two or several lines of systemic treatment.

In the EU, the drug has orphan drug designation to treat DLBCL and has been under regulatory review since October 2021 with a decision expected in Q1 2023.

The agreement should increase Sobi’s presence in orphan diseases within hematology. The drug would be marketed alongside other Sobi hematology drugs, including Doptelet.

For more health news, visit rttnews.com

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Related posts:

  1. Spain vs Poland UEFA EURO 2020 preview: where to watch, team news, predictions
  2. 10 things you didn’t know about Sofia Mattsson
  3. Join the hydrogen initiative with leading players to enable the rolling / milling of steel without fossil fuels
  4. Sweden supports the use of batteries and shore power to reduce emissions

Archives

  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021

Categories

  • Development agency
  • Major application
  • Sweden project
  • Swedish economy
  • Swedish international

Recent Posts

  • Palo Alto Networks Expands Checkov Tool to Secure Infrastructure
  • Hamburg Amazon Facility sits idle
  • Will TikTok Music be the next big podcast platform?
  • Iberdrola will acquire a portfolio of renewable projects in Poland
  • Illinois records second-lowest primary voter turnout in 40 years
  • Privacy Policy
  • Terms and Conditions